Search

Your search keyword '"He, Licai"' showing total 13 results
Start Over Author "He, Licai" Publication Year Range Last 3 years
13 results on '"He, Licai"'

5. Figure S5 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development

Author

Gui, Xun, primary, Deng, Mi, primary, Song, Hao, primary, Chen, Yuanzhi, primary, Xie, Jingjing, primary, Li, Zunling, primary, He, Licai, primary, Huang, Fangfang, primary, Xu, Yixiang, primary, Anami, Yasuaki, primary, Yu, Hai, primary, Yu, Chenyi, primary, Li, Leike, primary, Yuan, Zihao, primary, Xu, Xiaoying, primary, Wang, Qihui, primary, Chai, Yan, primary, Huang, Tao, primary, Shi, Yi, primary, Tsuchikama, Kyoji, primary, Liao, X. Charlene, primary, Xia, Ningshao, primary, Gao, George F., primary, Zhang, Ningyan, primary, Zhang, Cheng Cheng, primary, and An, Zhiqiang, primary

Published
2023
Full Text
View/download PDF

6. Table S1 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development

Author

Gui, Xun, primary, Deng, Mi, primary, Song, Hao, primary, Chen, Yuanzhi, primary, Xie, Jingjing, primary, Li, Zunling, primary, He, Licai, primary, Huang, Fangfang, primary, Xu, Yixiang, primary, Anami, Yasuaki, primary, Yu, Hai, primary, Yu, Chenyi, primary, Li, Leike, primary, Yuan, Zihao, primary, Xu, Xiaoying, primary, Wang, Qihui, primary, Chai, Yan, primary, Huang, Tao, primary, Shi, Yi, primary, Tsuchikama, Kyoji, primary, Liao, X. Charlene, primary, Xia, Ningshao, primary, Gao, George F., primary, Zhang, Ningyan, primary, Zhang, Cheng Cheng, primary, and An, Zhiqiang, primary

Published
2023
Full Text
View/download PDF

7. Data from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development

Author

Gui, Xun, primary, Deng, Mi, primary, Song, Hao, primary, Chen, Yuanzhi, primary, Xie, Jingjing, primary, Li, Zunling, primary, He, Licai, primary, Huang, Fangfang, primary, Xu, Yixiang, primary, Anami, Yasuaki, primary, Yu, Hai, primary, Yu, Chenyi, primary, Li, Leike, primary, Yuan, Zihao, primary, Xu, Xiaoying, primary, Wang, Qihui, primary, Chai, Yan, primary, Huang, Tao, primary, Shi, Yi, primary, Tsuchikama, Kyoji, primary, Liao, X. Charlene, primary, Xia, Ningshao, primary, Gao, George F., primary, Zhang, Ningyan, primary, Zhang, Cheng Cheng, primary, and An, Zhiqiang, primary

Published
2023
Full Text
View/download PDF

8. Additional file 1 of Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model

Author

Wu, Guang, Li, Lan, Liu, Mengnan, Chen, Chunyan, Wang, Guangze, Jiang, Zewei, Qin, Yaqian, He, Licai, Li, Hongzhi, Cao, Jiawei, and Gu, Haihua

Abstract

Additional file 1. Additional materials and methods. Figure S1. MMAE inhibits the growth of pancreatic cancer cells. Figure S2. Effect of Mc-vc-PABC linker on growth of pancreatic cancer cells. Figure S3. Expression of the MUC1 protein in Capan-2 and CFPAC-1 xenograft tumor tissues.

Published
2023
Full Text
View/download PDF

11. A novel humanized MUC1 antibody–drug conjugate for the treatment of trastuzumab-resistant breast cancer

Author

Wu, Guang, primary, Li, Lan, additional, Qiu, Yuxin, additional, Sun, Wei, additional, Ren, Tianhao, additional, Lv, Yingshuai, additional, Liu, Mengnan, additional, Wang, Xiaoxia, additional, Tao, Hongqun, additional, Zhao, Lingjie, additional, Cao, Jiawei, additional, He, Licai, additional, Li, Hongzhi, additional, and Gu, Haihua, additional

Published
2021
Full Text
View/download PDF

13. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.

Author

Wu G, Li L, Qiu Y, Sun W, Ren T, Lv Y, Liu M, Wang X, Tao H, Zhao L, Cao J, He L, Li H, and Gu H

Subjects
Animals, Antibodies, Monoclonal, Humanized metabolism, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological metabolism, Antineoplastic Agents, Immunological therapeutic use, Apoptosis drug effects, Breast Neoplasms blood, Breast Neoplasms pathology, Cell Cycle Checkpoints drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Drug Resistance, Neoplasm immunology, Epitopes, Humans, Immunoconjugates therapeutic use, Mice, Mice, Inbred BALB C, Mice, Nude, Mucin-1 blood, Mucin-1 chemistry, Mucin-1 immunology, Oligopeptides chemistry, Oligopeptides pharmacology, Oligopeptides therapeutic use, Receptor, ErbB-2 immunology, Receptor, ErbB-2 metabolism, Xenograft Model Antitumor Assays, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents, Immunological pharmacology, Breast Neoplasms drug therapy, Drug Resistance, Neoplasm drug effects, Immunoconjugates pharmacology, Mucin-1 metabolism, Trastuzumab pharmacology
Abstract

Mucin 1 (MUC1) has been regarded as an ideal target for cancer treatment, since it is overexpressed in a variety of different cancers including the majority of breast cancer. However, there are still no approved monoclonal antibody drugs targeting MUC1. In this study, we generated a humanized MUC1 (HzMUC1) antibody from our previously developed MUC1 mouse monoclonal antibody that only recognizes MUC1 on the surface of tumor cells. Furthermore, an antibody-drug conjugate (ADC) was generated by conjugating HzMUC1 with monomethyl auristatin (MMAE), and the efficacy of HzMUC1-MMAE on the MUC1-positive HER2+ breast cancer in vitro and in 'Xenograft' model was tested. Results from western blot analysis and immunoprecipitation revealed that the HzMUC1 antibody did not recognize cell-free MUC1-N in sera from breast cancer patients. Confocal microscopy analysis showed that HzMUC1 antibody bound to MUC1 on the surface of breast cancer cells. Results from mapping experiments suggested that HzMUC1 may recognize an epitope present in the interaction region between MUC1-N and MUC1-C. Results from colony formation assay and flow cytometry demonstrated that HzMUC1-MMAE significantly inhibited cell growth by inducing G2/M cell cycle arrest and apoptosis in trastuzumab-resistant HER2-positive breast cancer cells. Meanwhile, HzMUC1-MMAE significantly reduced the growth of HCC1954 xenograft tumors by inhibiting cell proliferation and enhancing cell death. In conclusion, our results indicate that HzMUC1-ADC is a novel therapeutic drug that can overcome trastuzumab resistance of breast cancer. HzMUC1-ADC should also be an effective therapeutic drug for the treatment of different MUC1-positive cancers in clinic., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results